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Introduction
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are used worldwide both as prescription and over-the-counter products for their analgesic, anti-inflammatory and cardiovascular disease (CVD) risk-reduction properties, and are among the most used pharmaceuticals in the world today 1 .
Chronic, low-dose use (commonly defined as 75-325 mg daily) of the NSAID Acetylsalicylic Acid (ASA) is widely recommended for both primary and secondary prevention of CVD. More than 30%
of the US population aged above 40 are estimated to be on chronic, daily, low-dose ASA for that reason alone 2 . However, chronic use of ASA is also associated with adverse side effects including small-intestinal mucosal lesions and ulcers, perforations, major hemorrhage and in rare instances death 3, 4, 5 . A recent review and meta-analysis addressing both the efficacy of ASA in prevention of CVD and also bleeding-related side-effects concluded that a balanced, cautious approach should be taken in the case of primary CVD prevention due to these side-effects 6 , highlighting the unmet need to reduce the risk of side-effects of chronic ASA use.
For decades endoscopists have acknowledged the vulnerability of the gastroduodenal mucosa to NSAID-induced enteropathy. Complications include ulceration, blood loss, protein loss, perforation and occasional strictures. The pathogenesis of tissue injury at the gastric and small-intestinal sites appears to differ 7, 8 , and therefore distinct and separate preventative strategies are probably required to combat enteropathy and gastropathy. For example, the risk of gastropathy can be offset by acid suppression, usually with proton pump inhibitors (PPIs). However, the pathogenesis of NSAIDinduced damage in the small bowel seems to be much more complex and has been shown to involve microbiota composition, bile and enterohepatic circulation of the certain NSAIDs 8 . Moreover, there is evidence to suggest that PPIs may actually increase the risk of NSAID-associated small bowel injury 9 , possibly by disturbing the composition of the small bowel microbiota 10 . The importance of M A N U S C R I P T
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6 associated with minimal damage to the small intestinal mucosa and co-administration of antibiotics reduces NSAID-induced injury 8, 7 . Besides the well-established inhibitory effect of cyclooxygenase (COX), ASA specifically has been recognised to compromise the phospholipid layer in mucus 11 increasing access to luminal aggressors like lipopolysaccharide and bile as well as disrupt intestinal permeability and cause inflammation 12 . Given that deleterious compositional changes to the microbiota, in addition to direct effects on mucus and epithelial tissue, may increase the risk of NSAID-enteropathy, we hypothesised that an intervention targeting microbiome-host interactions may offer an attractive, preventative strategy. Our strain selection was based on the antiinflammatory properties of certain bifidobacteria 13, 14 and experimental pre-clinical evidence for a role of bifidobacteria in NSAID-associated ulceration 15, 16, 17 as well as unpublished pre-clinical screening data suggesting a particular potential of efficacy for the specific strain belonging to this genus. In addition, another Bifidobacterium breve has been shown to express a pilus-associated protein (Tad E) in vivo, but not in vitro, which promotes colonic epithelial proliferation 18 .
Here, we describe the development of a clinical model to assess the quantitative and time-resolved induction of small intestinal injury upon ASA administration. Using this model, we addressed whether oral co-administration of a single bacterial strain of Bifidobacterium breve (Bif195) can reduce the risk of low-dose ASA-induced intestinal ulceration in humans in a randomized, placebocontrolled, parallel-group, double-blind trial using serial video capsule endoscopy (VCE) as a rigorous demonstration of efficacy.
Methods
Study design
This clinical trial was a single-site, randomized, double-blind, placebo-controlled, parallel-group, screening. After inclusion, subjects went through a two-week run-in period before baseline data were obtained at Visit 2 with randomization being performed at the very end of visit 2.
Randomization and masking
Prior to trial conduct, the allocation of subjects in a 1:1 ratio to Bif195 or placebo intervention was planned according to randomization lists. The randomization procedure was stratified by gender and the lists were drawn up to n=50 for each strata using the proc plan procedure in SAS.
Randomization blocks of n=6 was used throughout and trial site and sponsor were kept blinded to the use of randomization blocks. The randomization list and unblinding list were produced by a third party not otherwise involved in the trial.
At screening, subjects were assigned a 4-digit screening number according to their chronological entry into the trial. If a subject was found eligible and enrolled for trial participation, they received their randomization number by blinded trial staff after all baseline assessments performed at Visit 2.
Randomization numbers included the stratification number and was allocated sequentially by trial staff in the order in which the subjects completed Visit 2.
Test and placebo product were produced by the sponsor to be similar in smell, taste and appearance.
All trial product was packaged in identical packs with identical labelling, except for the randomization number. All trial subjects, the clinical team, statisticians and the sponsor were all blinded during the entire trial until database lock and signature of the request for unblinding document.
An emergency unblinding procedure using emergency code break opaque sealed envelopes was established to allow the investigator the option of disclosing the product assignment for any individual subject if clinical circumstances required such unblinding. This option was not used in the conduct of this trial. The randomization list and production of emergency code break envelopes
were performed by a third party not otherwise involved in the trial. The labeling of product vials, based on the randomization list, was also performed by a third-party not otherwise involved in the trial.
Procedures
Bif195 or placebo were administered in a 1:1 ratio daily to 75 randomized subjects for 8 weeks. To induce damage to the small intestine, all subjects were co-treated daily with 300 mg of ASA for the first 6 weeks of the 8 week Bif195/placebo intervention period.
In order to document small-intestinal damage, we performed VCE at 6 visits during the 8 week intervention period (Suppl. Figure 1 and Suppl. Figure 4 ). The time course kinetics of ASA-induced damage, as well as a potentially protective effect by Bif195, were expressed as area-under-the-curve (AUC) for the 8 week intervention period for all datasets obtained.
All subjects were given 2 hypromellose capsules daily with or without Bifidobacterium breve
Bif195 starting the day after visit 2 with a duration of 8 weeks. The product stability was monitored in parallel to trial conduct and showed at least 5*10 10 Colony forming units (CFU) of Bif195 per daily dose during the period of trial conduct. Detailed trial product and placebo description is provided in Supplementary Table 1 .
All randomized subjects were also given 300 mg of ASA (Alliance Pharmaceuticals, Ireland) to induce small-intestinal damage. This dose was taken daily from the day after visit 2 with a duration of 6 weeks.
VCE is the widely accepted reference standard for assessment of occult gastrointestinal bleeding.
Current use include exploration and surveillance of bowel pathology such as in Crohn's disease, polyps, small bowel malignancy and drug-induced mucosal injury 19 . To standardise the findings from VCE, we used a reproducible, clinical scoring system to categorise small intestinal mucosal damage, the Lewis score. The Lewis score is a validated tool that evaluates villous edema, ulcers M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
and stenosis in order to quantify small bowel inflammatory change in one score 20 . This scoring system uses specific definitions for each of the recorded parameters to reduce inter-reviewer variability. In addition, we also counted red spots as observed during VCE.
For all VCE analyses (visit 2-7), data were recorded using the SB3 TM Pillcam video recording capsule (Medtronic, Ireland). For all visits, subjects met fasting in the morning and the Pillcam capsule was swallowed with water. Video images were recorded for a total of 8 hours during each visit, after which the capsule was verified in the video to have passed the small intestine.
Four experienced gastroenterologists, blinded to intervention and not allowed to communicate internally regarding obtained VCE data, reviewed the video material retrieved from the capsules using the Pillcam TM Reader Software Version 9.0 from Medtronic. The VCE video material from all 6 VCE visits for each of the subjects were evaluated by two randomized reviewers, and mean values for each subject visit were calculated. In cases where the data from a specific visit differed with 4 or more number of ulcers, a third reviewer would review the VCE dataset. A mean value of all 3 datasets was then calculated and used as the final data point for that specific visit. All VCE reviews were performed prior to database lock and unmasking of the randomization key.
Representative pictures of the VCE material obtained are shown in Supplementary Figure 4 .
Fecal samples and blood samples were obtained during all visits from visit 2 to visit 7 for secondary and exploratory analyses.
At all visits, subjects completed the GI symptoms rating score (GSRS) questionnaire to assess GI symptoms 21 .
Intestinal fatty acid binding protein (I-FABP) was measured by Nordic Biosite, Finland, in triplicate heparin plasma samples using the HK406 human I-FABP ELISA kit from Hycult Biotech under GLP conditions.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
11
Serum calprotectin was measured in duplicate serum samples under GLP conditions by Nordic Biosite, Finland, using the HK379 Human Calprotectin ELISA kit from Hycult Biotech.
Fecal calprotectin was measured in duplicates under GLP conditions by Synlab, Switzerland, using an ELISA kit from Immundiagnostik AG, Germany.
Outcomes
The primary outcome of this trial was the effect of the Bif195 intervention on the AUC Lewis score obtained by VCE from visit 2 (randomization) to visit 7 (end of treatment). As the first secondary endpoint, the effect of the Bif195 intervention on the AUC number of ulcers obtained by VCE from visit 2 to visit 7 was tested. Other secondary endpoints were, in hierarchical order: AUC of the pain module from the GSRS questionnaire, AUC of the total score from the GSRS questionnaire, AUC of blood I-FABP, AUC of red spots from the VCE procedure, AUC of fecal calprotectin and AUC of blood calprotectin.
As exploratory endpoints, data stratified into tertiles (small intestine divided into thirds) on effects of the Bif195 intervention on ulcerations observed by VCE was analysed and further post-hoc analyses on intervention effects on prostaglandin E2 (PGE2) and thromboxane B2 (TBX2) in serum samples downstream of COX were studied.
Safety was assessed by means of adverse events. A complete list of adverse events is provided in Table 2 .
Statistical analysis
For all data obtained, area-under-the-curve (AUC) was calculated in order to evaluate the intervention effects by comparing the AUC in the Bif195 arm versus the placebo arm. For this purpose, the kinetics of Lewis score for each subject over the 6 VCE visits, was fitted to a third-M A N U S C R I P T
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12 degree polynomial and the total AUC was calculated by computing the integral. This approach was taken for all VCE-obtained data.
Statistical tests were pre-defined and agreed in the statistical analyses plan finalised and signed prior to unblinding of the randomization key. The randomization list was made, and the labelling of trial product was performed by third parties not otherwise involved in the trial. No imputation of data was carried out in cases of missing data, but all available data were used.
Subject characteristics and all efficacy data presented are based on the Full Analysis Set (FAS)
population. Criteria for inclusion in FAS was defined as maximum one missing visit in between the randomization visit (visit 2) and end of trial (Visit 7). The safety reporting by listing of adverse events included all subjects that were randomized (n=75)."
A sample size calculation was performed prior to trial initiation based on the primary endpoint of the trial. The curve shapes were assumed to fit with a third-degree polynomial. We considered a 30% lower AUC following treatment of Bif195 compared to placebo to be clinically relevant and aimed at a trial design that would have 80% power in detecting an intervention effects of this size as statistical significant. No previously knowledge exists on AUC values and SD. Sample size calculation was therefore performed on percent difference of AUC between two normalised curves (Active vs. placebo) as an approximation. We assumed similar standard deviation in each arm and planned for two-sided testing with a significance level of 5%. Given the above assumptions the number of subjects needed in each arm was 30. To account for potential drop-out subjects, we aimed to randomize a total of 75 subjects. Subjects who withdrew within one week of randomization were replaced by standby-subjects.
In general, datasets were modelled as the dependent variable in a linear mixed model. The model included the baseline value as covariate and gender and Bif195/placebo intervention as factors.
Model check was always assessed for all datasets using QQ residual plots together with M A N U S C R I P T
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Kolmogorov-Smirnov test for normality. In cases where datasets did not meet a normal distribution, a log transformation was performed and check for normality performed again. In cases where a normal distribution was still not obtained, the dataset was tested for intervention effects using a non-parametric Mann-Whitney test. Curves in Figure 2 ,3 and 5 are shown as mean values or medians, depending on normality. Bars in Figure 2 -5 are always shown as mean ± SEM.
All authors had access to the study data and reviewed and approved the final manuscript.
Results
Between July 31st, 2017 to October 24 th 2017, 109 subjects were screened for eligibility, of whom 75 were enrolled and randomized. Among the 75 randomized subjects, 9 subjects discontinued during the intervention (n=3 active and n=6 placebo) and therefore efficacy data was obtained in a total of 66 subjects, the analysis population (n=35 active arm and n=31 placebo, Figure 1 ).
The arms were in general similar in their baseline parameters as shown in Table 1 , including gender distribution, age, BMI and blood pressure. Accountability of both ASA and trial product were in general very high in both two arms (Table 1) .
This clinical trial met its primary endpoint with a statistically significantly (p=0.0376) lower AUC Lewis Score, as captured by VCE, during the 8 weeks intervention in the Bif195 arm versus the placebo arm (3040 ± 1340 arbitrary units (au) in the Bif195 arm vs 4351 ± 3195 au in the placebo arm, Figure 2A and B). In addition, the trial met its secondary endpoint with a significantly (p=0.0258) lower AUC ulcer number as captured using VCE during the intervention in Bif195 subjects versus the placebo group (50.4 ± 53.1 au in the Bif195 arm vs 75.2 ± 85.3 au in the placebo arm, Figure 2C and D).
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An exploratory tertile stratification of VCE data showed that the damage induced by ASA occurs primarily in the first tertile ( Figure 3 ) where a significant Bif195 protective effect (p=0.03) was also observed (31.0 ± 16.8 au in the Bif195 arm vs 41.6 ± 25.2 au in the placebo arm, Figure 3A and B).
The other secondary endpoints GSRS pain AUC, GSRA total score AUC, plasma I-FABP AUC, red spots from VCE AUC and serum calprotectin AUC did not meet statistical significance ( Figure   4 ) while fecal calprotectin AUC was significantly lower (p=0.0347) in the Bif195 arm compared to the placebo arm ( Figure 4E .) ASA and trial product were both generally well-tolerated by the subjects. In total, 32 adverse events were registered from 22 different subjects included in the n=75 safety analysis set. Twelve of these adverse events were reported from the Bif195 arm and 20 from the placebo arm ( Table 2 ). None of the adverse events were related to Bif195 intake, while in total 10 of them were assumed related to ASA intake, as assessed by the principal investigator. The number of adverse events related to ASA did not differ between the two intervention arms (4 and 6 in the Bif195 and placebo arm, respectively).
DNA sequencing of all fecal samples obtained showed an increase after randomization in abundance of Bifidobacterium breve in fecal samples obtained from subjects in the Bif195 arm compared to the placebo arm, confirming trial product compliance (Supplementary Figure 2) . The
Bif195 intervention was not associated with significant changes in abundance of specific microbial taxa nor in the changes of the overall microbiome composition (as revealed by Bray-Curtis dissimilarity index, Supplementary Figure 3) . Serum PGE2 and TXB2 concentrations showed a robust decline during ASA intake and a reversal to baseline levels during the final 2 weeks recovery period. The Bif195 intervention did not have significant effects on these datasets ( Figure 5 ).
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Discussion
The trial results indicate that Bifidobacterium breve Bif195 confers significant and objectively verifiable protection against small-intestinal damage caused by a 6 week ASA challenge in healthy volunteers. The primary and first secondary efficacy criteria for the trial were met, thereby highlighting the potential of Bif195 co-treatment in future prevention strategies for a growing population experiencing silent or overt small-intestinal enteropathy from chronic ASA use.
Although prior studies have described gastric damage from NSAIDs, this is, to the best of our knowledge, the first trial to record the detailed time-resolved kinetics of ASA-induced, and reversal of, small-intestinal damage. This dataset shows a gradual increase in damage observed by VCE during the 6 weeks of daily ASA intake and a partial reversal towards baseline levels over a 2-week recovery period. Furthermore, the small-intestinal tertile stratification clearly shows that ASAinduced enteropathy is mainly a duodenal phenomenon. This site coincides with localisation of the main effect of the Bif195 intervention on ulceration, further highlighting the potential of protective intervention with this strain. The strategy to perform serial capsule endoscopies in this trial, enabled us to obtain the sensitivity needed to observe a significant effect in a dynamic environment where damage formation and healing co-exists. Thus, it represents a superior and more sensitive form of assessment than the more usually adopted before/after intervention trial design.
The efficacy of Bif195 in NSAID-associated small intestinal injury may be partly explained by the difference in pathogenesis between NSAID-associated small intestinal injury and NSAID- investigation, but one candidate includes the pilus-associated protein Tad E which exerts a proliferative effect on host colonic epithelium following oral consumption of B. breve 18 . This appears to be a characteristic of all B. breve and supports our choice of the stain used in this trial.
Interestingly, fecal microbiome analysis revealed changes were limited to a marked increase in the total B. breve population in the Bif195 arm. These data provide further evidence that microbial intervention strategies targeting the microbiome can be clinically efficacious without inducing major alterations in the overall microbial population structure. Although encouraging, the present clinical trial has limitations in terms of translation to a real-life clinical setting. The relatively short-term challenge in healthy volunteers, for proof-of-concept, used a higher dose of ASA than is most commonly prescribed for primary CVD prevention. However, it is a dose that is readily available for over-the-counter usage. It is also noteworthy, that a recent report suggested that the current cardioprotective dosage of ASA may be insufficient and recommended doses based on a mg/kg basis 23 .
Due to our AUC approach based on a polynomic curve fitted to data-points obtained from 6 different visits, data imputation is not feasible for drop-out subjects where only baseline data are available. Therefore, we acknowledge that long-term intervention clinical trials will be needed to M A N U S C R I P T
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confirm if Bif195 has long-term clinical efficacy in a larger intention-to-treat population of chronic users of ASA taking lower doses for CVD prevention.
In addition, we acknowledge that the division of the small intestine into tertiles by VCE is based on assumptions and that tertile-specific data are an approximation.
As expected, the ASA intake was associated with robust inhibition downstream of the COX enzyme on serum PGE2 and TXB2 concentrations. It is noteworthy that the Bif195 intervention did not alter Compliance of ASA intake (%, 100% = product subj. should have taken during trial) 98.7 ± 2.4 99.1 ± 1.9
Compliance of trial product (%, 100% = product subj. should have taken during trial) 98.6 ± 2.4 99.0 ± 1.9
Body-mass index, BMI, is the weight in kilograms divided by the square of height in meters. Numbers are given as Mean ± SD. Sequencing reads were filtered to remove human and low-quality reads, mapped to the Clinical Microbiomics Human Gut 22M gene catalog, and summarised as a taxonomic relative abundance table as described previously 21 . The involved parties were kept blinded for intervention during analyses. Changes in relative abundances of taxa between visit 2 and the integral of later timepoints was tested using Wilcoxon rank sum test and corrected for multiple comparison using a Bonferroni correction. Similarly, the Bray-Curtis distance between visit 2 and later time-points were compared between the two arms (t-test).
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